Navigation Links
Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Date:10/30/2007

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that Adrian Adams has been elected to the company's Board of Directors effective immediately.

"We are very pleased to welcome Adrian to the Amylin Board," said Daniel M. Bradbury, President and CEO of Amylin Pharmaceuticals. "His international experience as a highly innovative, strategic business leader, combined with a track record of building organizations and delivering optimum results will enhance our Board's depth of experience."

Mr. Adams currently serves as President and CEO of Sepracor, Inc. Prior to this he was President and Chief Executive Officer of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. Mr. Adams has over 30 years of experience in both specialty and large pharmaceutical organizations that, in addition to Sepracor and Kos, included careers with ICI, SmithKline Beecham and Novartis, and involved work and product launches in most therapeutic areas. Mr. Adams has a broad background encompassing research and development, sales, international and national product marketing, business development and extensive general management experience.

He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree.

In addition to serving on the Amylin Board, Mr. Adams is actively involved as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America).

About Amylin

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Group promoting classified research elects officers
4. Miller Brewing selects Procuri software
5. Uniden selects Catalyst RFID software
6. Hammes Co. selects SiteStuff as procurement company
7. Meat-snack maker selects Prescient Applied Intelligence tech package
8. UW Colleges selects Allot Communications to manage multi-campus network
9. ProHealth Care selects NetScaler delivery system
10. Merkle selects Firstlogic data quality software
11. We Energies selects Frictionless SRM Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... F.E.E.D. Co., the Feline ... their revolutionary, veterinarian-designed product for indoor cats. The NoBowl Feeding System replaces the ... food the way nature intended. NoBowls make cats happy and healthy. , Since ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... is excited to announce the launch of the Proove Health Foundation . ... and education to promote the use of personalized medicine for tackling the nation’s ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a ... a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research ... at The Scripps Research Institute in San Diego, CA. , The aim ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):